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Objectives The primary aim of the study is to provide recommendations for the investigation and management of patients with
new onset anosmia during the COVID-19 pandemic Design After undertaking a literature review, we used the RAND/UCLA
methodology with a multi-step process to reach consensus about treatment options, onward referral imaging. Setting and
participants An expert panel consistent of 15 members was assembled. A literature review was undertaken prior to the study and
evidence was summarised for the panellists. Main outcome measures The panel undertook a process of ranking and classifying
appropriateness of different investigations and treatment options for new onset anosmia during the COVID-19 pandemic. Using
a 9-point Likert scale, panellists scored whether a treatment was: Not recommended, optional, or recommended. Consensus
was achieved when more than 70% of responses fell into the category defined by the mean. Results Consensus was reached
on the majority of statements after 2 rounds of ranking. Disagreement meant no recommendation was made regarding one
treatment, using Vitamin A Drops. Alpha lipoic acid was not recommended, olfactory training was recommended for all
patients with persistent anosmia of more than 2 weeks duration, and oral steroids, steroid rinses and omega 3 supplements may
be considered on an individual basis. Recommendations have been made regarding the need for referral and investigation have














































































































































referral guidelines and imaging for patients with COVID-19 related anosmia. The guideline may evolve as our experience of
COVID-19 develops.
Management of new onset anosmia during the COVID pandemic - BRS Consensus Guidelines
Running title
BRS Consensus guidelines for COVID anosmia
Abstract Objectives The primary aim of the study is to provide recommendations for the investigation and
management of patients with new onset anosmia during the COVID-19 pandemic
Design
After undertaking a literature review, we used the RAND/UCLA methodology with a multi-step process to
reach consensus about treatment options, onward referral
imaging.
Setting and participants
An expert panel consistent of 15 members was assembled. A literature review was undertaken prior to the
study and evidence was summarised for the panellists.
Main outcome measures
The panel undertook a process of ranking and classifying appropriateness of different investigations and
treatment options for new onset anosmia during the COVID-19 pandemic. Using a 9-point Likert scale,
panellists scored whether a treatment was: Not recommended, optional, or recommended. Consensus was
achieved when more than 70% of responses fell into the category defined by the mean.
Results Consensus was reached on the majority of statements after 2 rounds of ranking. Disagreement
meant no recommendation was made regarding one treatment, using Vitamin A Drops. Alpha lipoic acid
was not recommended, olfactory training was recommended for all patients with persistent anosmia of more
than 2 weeks duration, and oral steroids, steroid rinses and omega 3 supplements may be considered on an
individual basis. Recommendations have been made regarding the need for referral and investigation have
been made.
Conclusion This study identified the appropriateness of olfactory training, different medical treatment op-
tions, referral guidelines and imaging for patients with COVID-19 related anosmia. The guideline may evolve
as our experience of COVID-19 develops.
Keywords COVID-19, corona virus, anosmia, olfactory training, RAND/UCLA
Five succinct key points.
1. If the COVID status is unknown, serology should be performed for all patients with new onset smell
loss
2. Patients with Isolated loss of smell for less than three months may be managed by their GP.
3. When ENT referral is necessary, remote ENT consultation may be offered instead of a face-to-face
consultation depending on duration of symptoms and associated nasal symptoms
4. An MRI brain is not recommended for patients with COVID infection regardless of LOS duration.
5. Olfactory training is recommended to patients with LOS more than 2 weeks.
Introduction
At the time of writing (May 12th 2020), there have been 226,000 confirmed cases of COVID-19 in the UK.
Using data available through the COVID Symptom tracker which is monitoring over 2.5 million members of














































































































































The British Rhinological Society (BRS) and ENTUK were the first to report that loss of smell or taste
may be an important symptom. There has been a rapid growth in the evidence base supporting the initial
observations made by the BRS/ENTUK that an apparent rise in incidence of anosmia reflected the onset of
the COVID-19 pandemic(1-3).
We have undertaken a systematic review, which suggests a prevalence of self-reported loss of sense of smell
in 50% of patients. Emerging data suggests a high rate of early recovery, but at 4-6 weeks after onset
approximately 10% patients have not experienced any recovery and still self-report severe loss of sense of
smell. Applying the prevalence and recovery rates to estimated cases in the UK, there are likely already
more than 100,000 new cases of severe loss of sense of smell persisting beyond the first few weeks of COVID
infection. We do not yet know the potential for long term recovery, but we anticipate that both GPs and
ENT doctors will see an increase in the number of patients presenting for advice.
As there is a high rate of spontaneous recovery reported across all studies within 2 weeks of onset of
symptoms therefore we will consider only patients where duration of loss or reduction of sense smell (LOS),
with or without loss of sense of taste, is longer than 14 days or more. Furthermore, respiratory deterioration
typically occurs between day 7 – 12 after onset of symptoms and this period should be allowed to pass before
considering specific treatments, particularly as the safety of treatments in the setting of severe COVID-19
has yet to be fully established for any treatments considered.
Many patients report loss of flavour (due to loss of retronasal olfactory function) as loss of taste. Some
reports suggest that true taste disturbance is also present in COVID-19. However, we will not attempt to
differentiate or address this in this guidance, which will focus on self-reported loss of sense of smell
The aim of this guidance is to provide evidence-based recommendations for the management of patients
with COVID-19 related anosmia, while at the same time trying to optimise use of resources but ensuring
those with alternative pathologies are identified in a timely manner. We therefore considered investigation of
patients presenting with loss of sense of smell during the COVID pandemic and management of post-COVID
loss of sense of smell.
Material and Methods
An expert panel of 15 members was assembled, comprising of members of the BRS Council, members of an
ENTUK taskforce charged with developing guidance for outpatient practice in ENT and representatives of
the Global Consortium of Chemosensory Research.
A comprehensive literature review has been undertaken, by CH and MA, using Medline, Cochrane databases,
and MEdRxIv, and preprint server. Evidence was summarised for the panellists (Appendix 1), and where a
systematic review had been performed this was circulated in full. Studies were considered if they included any
patients with post-viral olfactory loss, or idiopathic loss. Some treatments identified by the literature review
were excluded if the evidence base showed that there were infective, or if the mode of administration could
not be supported during the pandemic (for example, repeated intravenous administration), or if regularly
face to face contact was required for administration or monitoring (Appendix 2). We used the RAND/UCLA
methodology with a multi-step process. Our expert panel undertook a process of ranking and classifying
appropriateness of different investigations and treatment options. Using a 9-point -Likert scale, panellists
scored whether a treatment was:
Not recommended: should not be undertaken or prescribed based on current evidence base as risks outweigh
likely benefits (1 -3),
Optional: could be undertaken or prescribed based on discussion with individual patient based on likely
risks versus benefits (4-6),
Recommended: should be undertaken or prescribed in all patients unless there are contraindications as














































































































































Free text comments were encouraged if greater context was required, if question were ambiguous or if anything
had been overlooked
Specific combinations of treatment were not considered as the evidence base does not currently have sufficient
data to evaluate for any enhanced effectiveness when used in combination. However multiple options could
be considered and recommended, and none of the treatments would be considered a contra-indication to use
of any others.
Upon receiving the results, the classification of recommendation was based on the mean ranking scores
collated from each clinical scenario provided that there was consensus.
Consensus was defined as the requirement for more than 70% of responses to fall into the category defined
by the mean, and when the mean score sits in ‘recommended’, less than 15% of responses fall into not
recommended, and vice versa. Where consencus was not reached items were reconsidered in a further round.
Disagreement was declared if more than 30% responses fell in both recommended and not recommended; in
this setting no recommendation could be given.
Panellists were given 72 hours to return their answers. The scores at the end of round 1 were analysed and
represented to the group, with each individual receiving a copy of their own initial evaluation. The panel
was then asked to repeat the scoring for any items where consensus had not been reached. After the second
round, any remaining items that had not reached consensus were further reviewed.
Results
Six items reached consensus at the end of round 1. Some questions were amended for the second round
in response to comments from panellists; for example, many panellists requested information on COVID
status and endoscopy findings in order to make recommendations. Steroid rinses were identified as a missing
treatment and added.
All panellists completed both rounds of the Delphi process.
After the second round, consensus had been achieved on most items. There was disagreement on the use of
Vit A drops and therefore no recommendations have been made in the guideline.
In 4 areas consensus could not be achieved at the 70% threshold, but was met at 60%. Further discussion
lead to consensus regarding imaging. The remaining items related to treatment using oral corticosteroids,
steroid drops or rinses and omega 3 supplements. The mean score for these items was 5, and 60 – 67%
considered these an option, and less than 15% would not recommend. They have been included as an option
but the uncertainty regarding the balance of risk and benefit should be discussed with the patient, and a
decision made on an individual basis.
Recommendations
ENT REFERRAL
Isolated loss of smell (LOS)
Patients with COVID infection
1. LOS less than three months:
2. The patient may be managed by their GP.
3. Anosmia advice sheets provided and treatment discussed (smell training and optional treatments out-
lined below)
4. LOS more than three months:
5. ENT referral.
6. Remote ENT consultation should be offered initially instead of a face-to-face consultation.














































































































































1. LOS more than 4-6 weeks:
2. ENT referral.
3. Remote ENT consultation may be offered instead of a face-to-face consultation.
4. LOS more than 3 months:
5. ENT referral.
6. A face-to-face ENT consultation should be considered to exclude other pathologies.
Patients with unknown COVID status
If the COVID status is unknown, serology should be performed for all patients with new onset smell loss. If
results unavailable, treat the patient as COVID positive if sudden onset loss of sense of smell
Loss of smell (LOS) associated with nasal symptoms
All patients with LOS more than 4-6 weeks associated with nasal symptoms should be referred to ENT for
consideration of a face-to-face consultation +/- nasendoscopy to exclude other pathologies.
Endoscopy findings should direct decisions regarding further imaging if possible.
INVESTIGATONS
COVID status should be established through history/PCR/serology in patients if possible.
Isolated loss of smell (LOS)
A) Patients with COVID infection (regardless of LOS duration)
An MRI scan of brain is not recommended
B) Patients with no COVID infection (LOS more than 3 months)
An MRI scan of brain is recommended if endoscopy is normal
C) Patients with unknown COVID status (LOS more than 3 months)
An MRI scan of brain is recommended if endoscopy is normal
Loss of smell (LOS) associated with nasal symptoms (regardless of COVID status)
Nasal endoscopy should be performed prior to imaging. However given the risks surrounding endoscopy and
limited availability, imaging may be requested first in selected cases.
If endoscopy is normal, further imaging is recommended (either MRI or CT).
Unilateral lesions or suspicion of malignancy on endoscopy needs urgent investigation with MRI/CT.
Benign findings (eg nasal polyps) should be treated medically before considering imaging.
Loss of smell (LOS) associated with neurological symptoms (excluding gustatory dysfunction)
All patients with LOS more than 6 weeks with additional neurological symptoms should have an MRI scan
of brain regardless of COVID-19 status.
MANAGEMENT
COVID status should be established through history/PCR/serology in patients if possible.
The recommendation is divided into:














































































































































Olfactory training and support
Olfactory training is recommended to patients with LOS more than 2 weeks.
It is recommended that anosmia advice is provided to the patients.
It is recommended that patients are directed to AbScent and Fifth Sense for further support.
Intranasal corticosteroid sprays
It is recommended in patients with LOS more than 2 weeks associated with nasal symptoms.
Intranasal corticosteroid drops or rinses
It is optional to recommend intranasal steroid drops or rinses in patients with LOS more than 2 weeks
associated with nasal symptoms.
Oral corticosteroids
It is not recommended to prescribe oral corticosteroids for a patient with LOS more than 2 weeks with
persistent COVID symptoms.
It is optional to recommend oral corticosteroids for a patient with LOS more than 2 weeks as an isolated
symptom or following resolution of any other COVID symptoms.
Vitamin A Drops
Due to disagreement within the group, it was not possible to make a recommendation regarding the use of
Vitamin A drops.
Alpha Lipoic Acid
It is not recommended for a patient with LOS more than 2 weeks as an isolated symptom or following
resolution of any other COVID symptoms.
Omega 3 supplements
It is optional for a patient with LOS more than 2 weeks as an isolated symptom or following resolution of
any other COVID symptoms. The flow chart (Figure 1) summarizes key points in relation to treatment,
investigations and management of new onset anosmia during the COVID 19 pandemic.
*Denotes items where consensus was achieved at 60% and not the 70% threshold, highlighting ongoing
uncertainty regarding usage. We therefore suggest that decisions regarding usage should be made at an
individual patient level, considering the risks in view of comorbidities and individual patient preferences
Discussion
Postviral olfactory loss (PVOL) is one of the most common causes of olfactory dysfunction. Pathogens include
those viruses causing the common cold comprising influenza-, parainfluenza-, rhino- and coronavirus(4).
Olfactory dysfunction can have a significant negative impact on quality of life(5). COVID-19 has been shown
to be associated with a high prevalence of loss of sense of smell and taste, and early reports on recovery
suggest that while this may be transient in many cases, resolving in 7-14 days, at least 10% will have severe
deficits lasting beyond the first 4 – 6 weeks(6). Longer term data is not yet available. Historical reports
of spontaneous recovery following post-viral loss likely exclude patients with transient loss due to under-
reporting, but instead capture those with loss persisting at least in beyond the first few weeks. Nevertheless,
two retrospective studies, including 791 and 262 patients respectively, indicate that between one third to two
thirds of patients with PVOL will experience a clinically relevant improvement(5, 7, 8). However, recovery
can sometimes take several years. Given the high incidence of COVID-19 it is anticipated that both primary














































































































































The applied RAND/UCLA methodology allowed for timely development of appropriateness criteria for the
medical management, referral guidelines, endoscopy and strategies for imaging of patients with new onset
anosmia. Indeed, time was the essence in this study as many doctors including general practitioners and
ENT surgeons are expected to meet a significant number of patients with post-COVID loss of sense of smell
in the near future (8). The flow chart created should assist with overview and appropriate management.
This methodology combined the best available evidence with the cooperative judgment of experts in the
field. There exists solid evidence for the use of olfactory training in the treatment of PVOL (5–7). Smell
training is also recommended by the expert panel in this study for the management of new onset anosmia
during the COVID-19 pandemic. Many different medications have been proposed to treat PVOL, including
oral corticosteroids, topical corticosteroids, zinc sulfate, alpha lipoic acid, theophylline, caroverine, vitamin
A, Ginkgo biloba, sodium citrate and minocycline. However, the evidence to support use of these med-
ical treatments for PVOL is limited and no large randomized controlled trials (RCT) exist. The expert
panel only recommended use of INCS in patients with anosmia and concomitant nasal symptoms and made
recommendations against the use of alpha lipoic acid.
We were unable to reach consensus at the 70% threshold determined a priori but did achieve consensus
at a 60% threshold for 3 treatments; topical steroid rinses, omega-3 supplements and oral corticosteroids
(but only if no symptoms of COVID or after full resolution of symptoms). We did agree that these could
be considered as optional medical treatments, but after discussion with patients regarding the uncertainty
surrounding usage and assessment of risks at an individual level.
Delivery of ENT care will be challenging as we undertake a graduated return to elective practice. In
particular, use of nasal endoscopy needs to be carefully considered due to its potential to be an aerosol
generating procedure. Waiting times for ENT care will likely significantly increase. For many patients with
confirmed COVID-19 infection and anosmia, specialist review and further investigation will not be required;
however, serology testing will be required for those who had been unable to access testing at the time of active
infection. We have identified those who will benefit from specialist review, and also provided supporting
material to assist primary care doctors, who may have had quite limited experience in this area. We plan to
develop further educational material for both GP’s and ENT surgeons. Patient groups including AbScent
and Fifth Sense will play an important role in patient support, we are delighted to be partnering with both
groups to provide patient information leaflets (Appendix 3) and further support through a variety of different
media.
A strength of the method was to give each panellist an equal voice in the Delphi process, and maintaining
anonymity throughout the scoring process. The methodology is also ideally suited to the social distancing
requirements of the current pandemic in place of nominal group techniques where face-to-face discussion is
required. A limitation is that the guidelines are based on the panellist’s interpretation of the best available
evidence and may be influenced by their own training and clinical experience. Another limitation may be
the group composition as it is generally recommended that the group is multidisciplinary(9); it would have
benefited from the inclusion of both primary care doctors and patient representatives.
We look forward to a time when the COVID pandemic will pass – and these guidelines no longer be needed.
They have been developed for a time when the prevalence of COVID-19 related loss of smell is high, but they
will need to be reconsidered when the relative likelihood of differential diagnoses increase – particularly with
regard to indications for further imaging. Although considered with regard to COVID-19 related anosmia,
the recommendations on treatments may be applied to all post-viral anosmia, although the risk – benefit
analysis may need to be modified. Finally, it should be noted that as our experience of COVID-19 grows,
our guideline will likely need to evolve. We hope that the newfound spotlight on loss of sense of smell and
taste will drive clinical research and lead to the development of novel treatment options for patients with
post-viral loss, and that greater understanding exists for those who do not recover.
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